Cerebrolysin is one of the most searched nootropic drugs in Ukraine and the wider CIS region, with thousands of monthly searches for the head term alone. Below we cover what Cerebrolysin is, its composition, how it works, why Cerebrolysin is not approved in some countries, what the reviews say, and which peptide analogs are studied for research purposes. This is educational content: Longeva does not sell Cerebrolysin and does not give medical advice.

Cerebrolysin: what it is

Cerebrolysin is an injectable peptide-based drug obtained from purified porcine (pig) brain protein through enzymatic breakdown. It is manufactured by the Austrian company EVER Pharma. It belongs to the group of neurotrophic (neurometabolic) agents: in a number of countries it is used in neurology for the aftermath of stroke, traumatic brain injury and dementia. It is given intravenously or intramuscularly, so it is a prescription medical drug, not a supplement or a "memory pill".

Cerebrolysin composition

The composition of Cerebrolysin is an aqueous solution of a mixture of low-molecular-weight peptides (below ~10 kDa) and free amino acids. The active fraction is roughly 25% of the concentrate, and the rest is water for injection. The developers' idea is that the short peptides in this mixture resemble fragments of natural neurotrophic factors in size and structure. This peptide nature of the composition is what the claimed neuroprotective effect is attributed to.

How Cerebrolysin works

Its mechanism is described as "neurotrophic-like": according to preclinical research, Cerebrolysin peptides can influence neuronal survival, synaptic plasticity and neurogenesis. In part they mimic the action of the brain's own growth factors (such as BDNF and GDNF). The evidence has a clear limit: many of these effects were shown in cell and animal models, while the results of human clinical trials remain inconsistent.

Why Cerebrolysin is banned in some countries

A more accurate wording is "not registered / not approved" rather than "banned". Cerebrolysin is registered in around 50 countries (including Ukraine and many countries in Asia and Latin America), but it is not on the approved-drug list of the United States (FDA), the United Kingdom or several Western European countries. The main reasons are:

  • Regulators lack large, high-quality randomized trials that would clearly confirm a clinical benefit. Reviews (including a Cochrane review on acute ischaemic stroke) found no convincing effect.
  • The drug is of animal origin (pig brain), which adds requirements around standardization, batch control and theoretical biosafety questions.
  • A composition that is a mixture of many peptides is harder to standardize and reproduce than a single pure molecule.

So the "ban" is really the absence of registration due to an evidence base these regulators consider insufficient, rather than a conclusion about harm.

Cerebrolysin reviews: what to keep in mind

Reviews of Cerebrolysin online vary widely: some people describe improved focus and well-being, others notice no effect. This is expected, since subjective reviews do not account for the placebo effect, concurrent treatment and natural recovery after a stroke or injury. Relying on reviews alone to judge the drug is not advisable: they are no substitute for controlled studies and a doctor's consultation.

Peptide analogs of Cerebrolysin for research

Because interest in Cerebrolysin is largely tied to its peptide, neurotrophic-like concept, the research community studies individual short peptides that follow a similar logic. Longeva supplies such compounds strictly for laboratory and research use, with a COA (Certificate of Analysis, a batch-specific lab certificate) for every batch and verified purity. They are not medicines and not therapeutic equivalents of Cerebrolysin.

  • P21 (P021): a peptidomimetic studied as a neurotrophic factor mimetic. In preclinical work it is linked to stimulating neurogenesis and increasing BDNF.
  • Pinealon: a short peptide studied in cell and animal models for neuroprotective and antioxidant properties.

These materials help compare mechanisms and understand how short synthetic peptides differ from an animal-derived mixture like Cerebrolysin.

Summary

Cerebrolysin is a prescription, animal-derived peptide drug with an inconsistent evidence base, which explains its varying regulatory status around the world. If your interest is scientific and research-oriented, consider individual short peptides with a transparent purity profile. Leave any questions of use to a physician. This text is for educational purposes only.